Dr. Fidler on the Utility of Dacomitinib in EGFR-Mutant NSCLC

Dr. Fidler Discusses Osimertinib in EGFR-Mutated Lung CancerПодробнее

Dr. Fidler on the FLAURA Trial in EGFR-Mutant NSCLCПодробнее

Dr. Low on Osimertinib Versus Dacomitinib in EGFR-Mutant NSCLCПодробнее

Dacomitinib in Treatment-Naïve EGFR-Mutated NSCLC: Real-World Insights from India | CRSFПодробнее

Dr. Kris on the FDA Approval of Dacomitinib in EGFR+ NSCLCПодробнее

Dr. Fidler on RELAY Trial Results in EGFR+ NSCLCПодробнее

Dr. Shum Discusses Dacomitinib in EGFR+ NSCLCПодробнее

Dacomitinib: new treatment paradigm in the management of EGFR mutation positive NSCLCПодробнее

Dr. Mark Kris Discusses Dacomitinib for Patient with EGFR-Positive Lung CancerПодробнее

Dr. Wakelee Discusses Dacomitinib in EGFR+ NSCLCПодробнее

Dr. Bertino on Frontline Dacomitinib in Metastatic EGFR+ NSCLCПодробнее

Dacomitinib (EGFR Inhibitor) for Lung Cancer Patients - What is it?Подробнее

Dr. Piotrowska on Treatment for EGFR-Mutant NSCLCПодробнее

Repeat biopsy in lung cancer patients with EGFR mutationПодробнее

Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLCПодробнее

Overview of the world of EGFR mutant lung cancersПодробнее

TKIs to treat EGFRm-positive NSCLCПодробнее

Is Dacomitinib Survival Benefit Enough to Make it a Contender as First Line Treatment? (BMIC-044)Подробнее

Treatment of EGFR+ NSCLC After OsimertinibПодробнее